NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/22/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,798.09 mln
Float52.12 mln
Earnings Date08/11/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.46
Borderline
1-Year Forecast
62.83
Strong upside
Relative Strength
18
/ 100
Significantly lagging
Debt / Equity
0.04
Debt-free
ROE
-2.75
Negative
Business Description
Supernus Pharmaceuticals is a US-based company focused on developing and selling medicines that treat brain and nervous system conditions. Its current lineup includes treatments for ADHD, Parkinson's disease, epilepsy, cervical dystonia, and chronic sialorrhea, sold through wholesalers, specialty pharmacies, and distributors. The company also has several drugs in clinical trials targeting epilepsy, treatment-resistant depression, and ADHD. Founded in 2005 and headquartered in Rockville, Maryland, Supernus continues to grow its portfolio through internal research and external development partnerships.
